Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News FDA approves Luxturna gene therapy for inherited vision loss In a significant advancement for medical science, Luxturna (voretigene neparvovec), developed by Spark Therapeutics, has been approved by… bypharmanewsdailyDecember 30, 2017